AntriaBio seeks FDA nod for trial of once-weekly insulin
AntriaBio (OTC:ANTB) said today that it filed an investigational new drug application with the FDA for its once-weekly basal insulin.
If the Louisville, Colo.-based company wins approval from the FDA, it plans to launch a Phase I clinical trial of AB101 in patients with Type I diabetes.
Get the full story at our sister site, Drug Delivery Business News.
The post AntriaBio seeks FDA nod for trial of once-weekly insulin appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat antriabio Source Type: news
More News: Clinical Trials | Diabetes | Endocrinology | Insulin | Investigational New Drugs | New Drug Applications